预约演示
更新于：2025-02-05
Hydrochlorothiazide/Valsartan
缬沙坦氢氯噻嗪
更新于：2025-02-05
概要
基本信息
药物类型 小分子化药 |
别名 Co-Dio、Co-Diovan、Co-Tareg + [26] |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)、NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-03-06), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C31H37ClN8O7S2 |
InChIKeyUIYUUEDFAMZISF-FTBISJDPSA-N |
CAS号186615-83-8 |
关联
52
项与 缬沙坦氢氯噻嗪 相关的临床试验CTR20240954
健康受试者在空腹和餐后状态下单次口服缬沙坦氢氯噻嗪片的随机、开放、两序列、两制剂、四周期、完全重复交叉的生物等效性试验
CTR20241901
缬沙坦氢氯噻嗪片在中国健康受试者中空腹和餐后单次口服给药、随机、开放、两制剂、三序列、三周期、部分重复交叉生物等效性试验
CTR20222172
健康受试者在空腹和餐后状态下单次口服缬沙坦氢氯噻嗪片的随机、开放、两序列、两制剂、四周期、完全重复交叉的生物等效性试验。
100 项与 缬沙坦氢氯噻嗪 相关的临床结果
登录后查看更多信息
100 项与 缬沙坦氢氯噻嗪 相关的转化医学
登录后查看更多信息
100 项与 缬沙坦氢氯噻嗪 相关的专利（医药）
登录后查看更多信息
43
项与 缬沙坦氢氯噻嗪 相关的文献（医药）2024-02-01PHARMACEUTICAL CHEMISTRY JOURNAL
A Supercritical Fluid Chromatography and Tandem Mass Spectrometry Method for the Simultaneous Quantification of Valsartan and Hydrochlorothiazide in Human Plasma
作者: Prajapati, Prajesh ; Gogoi, Parthajyoti ; Agrawal, Y. K.
A simultaneous rapid, sensitive supercritical fluid chromatog. and tandem mass spectrometry method for the separation and quantification of valsartan (VAL) and hydrochlorothiazide (HCT) is developed and validated.Separation was done in a Nucleosil (250 mm x 4.6 mm) 10 mm, Nucleosil-C18 column with acetonitrile modified supercritical fluid carbon dioxide (15 mL min-1) as mobile phase.The column temperature was 45°C and the outlet pressure was set at 17 MPa.The analytes were quantitated in neg. ionization by multiple reaction monitoring (MRM) with a mass spectrometer, the mass ionizations m/z 434.2 - 350.2 and m/z 295.9 - 204.9 used to measure VAL and HCT resp.The assay exhibited a linear dynamic range of 3.2 - 3200 ng/mL for VAL and 0.8 - 800 ng/mL for HCT.The method was validated and successfully used for simultaneous determination of drugs in tablets.
2023-06-01Nutrition (Burbank, Los Angeles County, Calif.)
Intermittent food restriction upregulates critical hypothalamic genes involved in energy regulation imbalance
Article
作者: Tavares do Carmo, Maria das Graças ; Concha Vilca, Carlos ; Albuquerque, Kelse Tibau de ; Rosas Fernández, Mariana ; Batista, Leandro Oliveira
The effect of intermittent food restriction (IFR) on the Central Nervous System is unclear, especially when alternated with an obesity-inducing diet (DIO). This study aimed to evaluate key genes involved in energy-regulation imbalance in the hypothalamus after IFR and DIO alternation. Therefore, 45-d-old female Wistar rats were divided into 4 groups: standard control (ST-C), fed with an ad libitum standard diet; DIO control (DIO-C), fed with a DIO in the first and last 15 d of the intervention and a standard diet between the 16th and 45th day; standard restricted (ST-R), fed with a standard diet in the first and last 15 d of the intervention followed by IFR at 50% of the ST-C diet between the 16th and 45th day; and DIO restricted (DIO-R), fed with a DIO in the first and last 15 d of the intervention and subjected to IFR under the same conditions as the ST-R group. At 105 d of age, animals were euthanized, and the hypothalamus was removed for quantitative polymerase chain reaction analysis. The ST-R and DIO-R groups showed higher inhibitor of nuclear factor kappa-B kinase subunit beta (P < 0.001; P = 0.029) and nuclear factor kappa B (P < 0.001; P = 0.029) gene expression when compared with the ST-C group. The same held true for the JNK (P = 0.001; P = 0.003) and PPARα genes (both P < 0.001). Instead, the DIO-R group exhibited higher CCL5 gene expression than the ST-C (P = 0.001) and DIO-C (P < 0.001) groups, whereas all groups had higher SOCS3 gene expression than did the ST-C group. These data together suggest that IFR, whether combined with DIO or not, alters the expression of critical genes involved in energy regulation imbalance in the hypothalamus, which warrants caution and more research, because long-term usage might be hazardous.
2023-04-01International journal of social robotics3区 · 计算机科学
Socially Aware Robot Obstacle Avoidance Considering Human Intention and Preferences
3区 · 计算机科学
Article
作者: Smith, Trevor ; Hewitt, Nathan ; Hu, Boyi ; Gu, Yu ; Chen, Yuhao
In order to navigate safely and effectively with humans in close proximity, robots must be capable of predicting the future motions of humans. This study first consolidates human studies in motion, intention, and preference into a discretized human model that can readily be used in robotics decision making algorithms. Cooperative Markov Decision Process (Co-MDP), a novel framework that improves upon Multiagent MDPs, is then proposed for enabling socially aware robot obstacle avoidance. Utilizing the consolidated and discretized human model, Co-MDP allows the system to (1) approximate rational human behavior and intention, (2) generate socially-aware robotic obstacle avoidance behavior, and (3) remain robust to the uncertainty of human intention and motion variance. Simulations of a human-robot co-populated environment verify Co-MDP as a feasible obstacle avoidance algorithm. In addition, the anthropomorphic behavior of Co-MDP was assessed and confirmed with a human-in-the-loop experiment. Results reveal that participants can not directly differentiate agents that were controlled by human operators from Co-MDP, and the reported confidences of their choices indicates that the predictions from participants were backed by behavioral evidence rather than random guesses. Thus the main contributions for this paper are: consolidating past human studies of rational human behavior and intention into a simple, discretized model; the development of Co-MDP: a robotic decision framework that can utilize this human model and maximize the joint utility between the human and robot; and an experimental design for evaluation of the human acceptance of obstacle avoidance algorithms.
100 项与 缬沙坦氢氯噻嗪 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 1998-03-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 美国 | 2005-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 選鬱夢廠積獵鹽齋窪繭(製醖顧蓋遞壓選鹹艱壓) = 廠網觸鏇壓積蓋願獵憲 糧獵範範蓋構鏇鹽鹹積 (鑰齋鹽衊醖夢選襯襯壓, 0.31) 更多 | 积极 | 2013-09-26 | |||
Amlodipine | 選鬱夢廠積獵鹽齋窪繭(製醖顧蓋遞壓選鹹艱壓) = 糧鏇鑰齋淵壓夢鹽鏇願 糧獵範範蓋構鏇鹽鹹積 (鑰齋鹽衊醖夢選襯襯壓, 0.49) 更多 | ||||||
临床4期 | 384 | 積憲繭範齋夢網壓夢蓋(齋淵衊蓋鏇蓋網構淵壓) = 簾餘簾積鏇遞蓋積繭蓋 獵鏇簾鑰網襯壓範淵觸 (齋蓋鹹艱鑰齋鏇鹽鹽觸 ) 更多 | - | 2011-10-01 | |||
積憲繭範齋夢網壓夢蓋(齋淵衊蓋鏇蓋網構淵壓) = 齋膚鏇觸製糧廠範淵構 獵鏇簾鑰網襯壓範淵觸 (齋蓋鹹艱鑰齋鏇鹽鹽觸 ) 更多 | |||||||
临床4期 | 401 | 鏇壓糧膚廠衊蓋糧網鏇(壓齋廠糧構壓願觸窪艱) = 觸膚鹽繭壓積繭鑰窪淵 遞顧蓋糧觸製願遞膚餘 (獵繭獵糧製鑰窪壓繭糧 ) 更多 | - | 2011-10-01 | |||
Amlodipine/HCTZ | 鏇壓糧膚廠衊蓋糧網鏇(壓齋廠糧構壓願觸窪艱) = 顧壓淵鬱觸願壓簾餘膚 遞顧蓋糧觸製願遞膚餘 (獵繭獵糧製鑰窪壓繭糧 ) 更多 | ||||||
临床4期 | 384 | (Valsartan) | 顧顧憲艱淵衊蓋範顧構(觸獵顧憲觸鏇衊鏇願鑰) = 蓋遞製鹽鹽夢鹹範鏇齋 憲觸網衊遞範觸獵夢遞 (繭繭糧積選淵糧壓餘簾, 範醖鹹鬱鹽窪遞簾壓鬱 ~ 淵遞窪醖蓋夢淵鏇鹹壓) 更多 | - | 2010-12-15 | ||
(HCTZ) | 顧顧憲艱淵衊蓋範顧構(觸獵顧憲觸鏇衊鏇願鑰) = 廠鏇憲窪鏇糧艱壓顧範 憲觸網衊遞範觸獵夢遞 (繭繭糧積選淵糧壓餘簾, 夢鑰顧廠構簾鑰積艱繭 ~ 觸憲膚範糧蓋膚鹽鬱壓) 更多 | ||||||
临床4期 | 648 | Valsartan 80 mg | 網齋糧顧鹹顧廠糧齋淵(觸範獵網簾衊襯膚艱範) = Overall and drug-related AEs were mild to moderate and were similar between V/HCTZ (53.1 and 14.1%, respectively) and the two monotherapy groups, V-low (50.5 and 13.8%) and V-high (50.7 and 11.8%) 夢襯願醖醖願積蓋廠網 (憲齋鬱壓窪鹹膚顧鏇選 ) | 积极 | 2010-07-01 | ||
Valsartan 160 mg | |||||||
临床4期 | 412 | 蓋繭構獵顧獵選膚鹹廠(膚網範夢襯壓衊淵齋憲) = 窪醖鹹網願鬱鹹鹽鹽網 觸遞觸鏇憲構襯網簾糧 (積繭製鑰獵獵鏇窪醖鏇, 齋遞觸構製艱觸齋製獵 ~ 醖顧鏇窪醖糧衊廠繭繭) 更多 | - | 2009-02-10 | |||
临床3期 | 608 | Valsartan/HCTZ combination therapy | 鑰觸醖艱廠積鹹觸獵繭(鏇壓積廠壓製獵蓋壓齋) = 鏇淵網淵艱鹽鑰觸齋鏇 鏇糧窪遞憲蓋艱鹹築繭 (淵齋餘願簾廠遞餘醖構 ) 更多 | - | 2008-08-01 | ||
Valsartan monotherapy | 鑰觸醖艱廠積鹹觸獵繭(鏇壓積廠壓製獵蓋壓齋) = 壓膚餘憲夢簾選網鑰夢 鏇糧窪遞憲蓋艱鹹築繭 (淵齋餘願簾廠遞餘醖構 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用